Correlation Between Citius Oncology, and Connect Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Citius Oncology, and Connect Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Citius Oncology, and Connect Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Citius Oncology, and Connect Biopharma Holdings, you can compare the effects of market volatilities on Citius Oncology, and Connect Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Citius Oncology, with a short position of Connect Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Citius Oncology, and Connect Biopharma.

Diversification Opportunities for Citius Oncology, and Connect Biopharma

0.65
  Correlation Coefficient

Poor diversification

The 3 months correlation between Citius and Connect is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Citius Oncology, and Connect Biopharma Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Connect Biopharma and Citius Oncology, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Citius Oncology, are associated (or correlated) with Connect Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Connect Biopharma has no effect on the direction of Citius Oncology, i.e., Citius Oncology, and Connect Biopharma go up and down completely randomly.

Pair Corralation between Citius Oncology, and Connect Biopharma

Given the investment horizon of 90 days Citius Oncology, is expected to under-perform the Connect Biopharma. In addition to that, Citius Oncology, is 1.54 times more volatile than Connect Biopharma Holdings. It trades about -0.1 of its total potential returns per unit of risk. Connect Biopharma Holdings is currently generating about 0.02 per unit of volatility. If you would invest  109.00  in Connect Biopharma Holdings on January 4, 2025 and sell it today you would lose (50.00) from holding Connect Biopharma Holdings or give up 45.87% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy32.79%
ValuesDaily Returns

Citius Oncology,  vs.  Connect Biopharma Holdings

 Performance 
       Timeline  
Citius Oncology, 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Citius Oncology, has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in May 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Connect Biopharma 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Connect Biopharma Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in May 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Citius Oncology, and Connect Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Citius Oncology, and Connect Biopharma

The main advantage of trading using opposite Citius Oncology, and Connect Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Citius Oncology, position performs unexpectedly, Connect Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Connect Biopharma will offset losses from the drop in Connect Biopharma's long position.
The idea behind Citius Oncology, and Connect Biopharma Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEOs Directory
Screen CEOs from public companies around the world
Equity Valuation
Check real value of public entities based on technical and fundamental data
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing